MRI Muscle in Metabolic and Systemic Muscle Disorders — Generic Standard Protocol
Required Protocol at a Glance
Mandatory core sequences for this examination. Detailed rationale, conditional additions and optimisation notes are provided later in the protocol.
MRIninja Knowledge Base | Master / General Protocol Page Anatomical domain: skeletal muscle of the limbs, girdle, and trunk in the context of acute and chronic metabolic, toxic, endocrine, and systemic-disease-related muscle injury Version 1.0 — July 2026
1. Executive Summary
This master page covers the generic MRI approach to skeletal muscle involvement by processes that are not primarily traumatic, neoplastic/infective, or classically neurogenic/inherited-myopathic — the domains already addressed by the companion MRIninja muscle master pages — but instead arise from an acute metabolic insult, a systemic vascular or granulomatous disease, an endocrine derangement, or drug/toxin exposure. This is a deliberately heterogeneous indication group, spanning: rhabdomyolysis (acute, potentially life-threatening myocyte breakdown from any cause); diabetic myonecrosis (diabetic muscle infarction); endocrine myopathies (thyroid, parathyroid, adrenal); drug-induced myopathy (statins, corticosteroids, and other agents); other toxic myopathies; electrolyte-disorder-related muscle injury; mitochondrial myopathies; and systemic diseases with muscle involvement, most importantly vasculitis and sarcoidosis. What unites this group, and what justifies a single generic master page rather than scattering these entities across the trauma, tumor/infection, or neuromuscular pages, is that MRI plays a broadly similar technical role across all of them — detecting and characterising oedema-like signal, necrosis, and focal pseudotumoral change against a background of systemic or metabolic disease — even though the underlying pathophysiology, urgency, and clinical management differ enormously between, say, acute rhabdomyolysis and chronic corticosteroid-induced muscle atrophy.
The role of MRI differs sharply by sub-entity. In acute rhabdomyolysis, MRI is not the primary diagnostic test — that role belongs to serum creatine kinase and clinical assessment — but MRI is valuable for mapping the extent and distribution of muscle involvement, detecting myonecrosis and intramuscular haemorrhage, and helping identify a complication such as an evolving compartment syndrome or an underlying local cause (e.g., an unsuspected localising injury), particularly when the clinical presentation and laboratory findings are atypical or when a co-existing surgical problem must be excluded. In diabetic myonecrosis, sarcoid myopathy, and vasculitic myopathy, MRI has a genuinely central diagnostic role: it is frequently the modality that first raises or confirms the correct diagnosis, guides or obviates biopsy, and defines disease extent, because each of these entities has a describable, sometimes near-specific pattern of muscle and perimuscular signal change. In endocrine, drug-induced (including statin), toxic, electrolyte-related, and mitochondrial myopathies, MRI is frequently normal or shows only non-specific atrophy, oedema, or fatty change, and the diagnosis in these entities rests predominantly on clinical, biochemical, pharmacological, and genetic/histological grounds rather than on imaging; MRI’s role here is more to exclude an alternative structural explanation for symptoms, or to characterise the pattern of chronic change, than to establish the diagnosis itself.
Compared with CT, MRI offers far superior soft-tissue contrast for detecting muscle oedema, necrosis, and haemorrhage, and avoids ionising radiation in a population that may require repeated imaging; CT retains a role mainly for excluding calcification, gas, or an alternative acute surgical diagnosis when MRI is not immediately available. Compared with ultrasound, MRI provides more comprehensive, less operator-dependent, and more anatomically complete assessment, particularly for deep muscle compartments and for the many entities in this group (sarcoid nodules, vasculitic lesions) whose lesions can be small, deep, and easily missed on a limited-window ultrasound survey. Scintigraphy (e.g., gallium-67) retains a historical role in some systemic granulomatous disease work-ups but has been substantially superseded by MRI for the specific question of muscle involvement.
This generic protocol is designed to detect, localise, and broadly characterise muscle oedema-like signal, necrosis, haemorrhage, and focal pseudotumoral lesions across this diverse indication group. It is not designed to:
- serve as the primary diagnostic or severity-grading test for rhabdomyolysis, which remains a clinical and biochemical (creatine kinase, renal function) diagnosis;
- provide a specific biochemical, genetic, or histological diagnosis for endocrine, toxic, drug-induced, electrolyte-related, or mitochondrial myopathy, most of which have normal or non-specific MRI appearances;
- replace muscle biopsy where histological confirmation is required, though it can guide the biopsy site and, in several of the entities covered here, meaningfully reduce the number of patients who need biopsy at all;
- provide whole-body coverage by default; this generic page describes a regional protocol and, as in the companion neuromuscular master page, explicitly routes to a dedicated whole-body/multi-segment protocol when systemic or multifocal disease (e.g., extensive vasculitis, sarcoidosis, or suspected multifocal rhabdomyolysis) requires it;
- manage the underlying systemic disease itself — imaging findings must be interpreted alongside the relevant medical, endocrinological, rheumatological, or nephrological work-up rather than in isolation.
1.1 Core strengths
- High sensitivity for detecting and mapping oedema-like signal and necrosis in acute muscle breakdown, supporting extent assessment and complication detection in rhabdomyolysis.
- Ability to characterise a focal pseudotumoral muscle lesion (diabetic myonecrosis, nodular sarcoid myopathy) with enough specificity, in the right clinical context, to avoid an unnecessary biopsy or to guide one confidently when required.
- Depiction of a perivascular or fascial pattern of enhancement and oedema that can support a vasculitic aetiology, complementing clinical and serological assessment.
- Non-invasive, repeatable, radiation-free imaging suitable for the serial follow-up that several of these conditions (evolving rhabdomyolysis, treated sarcoid myopathy) require.
1.2 Intrinsic limitations of the generic protocol
A generic protocol for this heterogeneous indication group is a compromise between breadth, acquisition time, and diagnostic specificity, and the honest limitation to state up front is that for a large share of the entities nominally covered by this page, MRI is expected to be normal or non-specifically abnormal, and a normal MRI does not exclude the diagnosis.
- Endocrine, most drug-induced, toxic, electrolyte-related, and mitochondrial myopathies frequently show a normal or only mildly, non-specifically abnormal MRI; the diagnostic burden for these entities rests on clinical assessment, laboratory testing, medication history, and, where indicated, genetic testing or biopsy, and the generic protocol should not be over-relied upon to “rule out” these conditions.
- Oedema-like signal is non-specific across this entire indication group, exactly as in the companion trauma and neuromuscular pages: rhabdomyolysis, diabetic myonecrosis, vasculitic myopathy, sarcoid myopathy, and inflammatory myopathy (covered on the neuromuscular master page) can all produce overlapping fluid-sensitive signal change, and distribution pattern, clinical context, and laboratory data are essential for correct attribution.
- A single-region protocol may miss a second site of involvement in a systemic or multifocal process (bilateral diabetic myonecrosis, multifocal sarcoid nodules, multi-territory vasculitis), and coverage decisions should be explicitly informed by the systemic clinical picture rather than defaulting to the single symptomatic region.
- Contrast plays a variable, entity-dependent role in this indication group, unlike the more uniform approach in the companion trauma protocol; this is addressed explicitly in Section 6.
- Severity of rhabdomyolysis cannot be graded by MRI in the way that serum creatine kinase and renal function can; MRI extent findings correlate imperfectly with systemic severity and must never substitute for laboratory monitoring.
2. Main Clinical Indications
2.1 Standard Indications
The generic protocol is appropriate for a wide range of referrals in this indication group, each with a different balance of diagnostic reliance on imaging. In suspected or confirmed rhabdomyolysis with an atypical distribution, an unclear inciting cause, disproportionate localised findings, or clinical concern for a local complication (myonecrosis, compartment syndrome, an underlying focal injury), MRI is useful to map extent and detect these complications, though the generic protocol is not required for the many straightforward, biochemically clear-cut cases managed on clinical and laboratory grounds alone. In a diabetic patient with acute, severe, unilateral thigh or calf pain and swelling without a clear infective or traumatic cause, particularly with long-standing, poorly controlled diabetes and microvascular complications, the generic protocol is usually sufficient to establish or strongly support a diagnosis of diabetic myonecrosis and to exclude its principal mimickers. In a patient with known or suspected sarcoidosis presenting with palpable muscle nodules, myalgia, or unexplained muscle weakness, the generic protocol can characterise the pattern (nodular versus diffuse/myopathic) and support treatment monitoring. In a patient with known or suspected systemic vasculitis (e.g., polyarteritis nodosa, ANCA-associated vasculitis) presenting with muscle pain, tenderness, or a palpable mass-like area, MRI can support the diagnosis and help direct biopsy. In suspected endocrine, drug-induced (including statin-associated), toxic, or electrolyte-related myopathy, the generic protocol is most useful to exclude an alternative structural or inflammatory explanation for symptoms, understanding that a normal study does not exclude these diagnoses, which remain predominantly clinical/biochemical. A dedicated child protocol becomes necessary once the clinical picture points to a specific need: whole-body or extended multi-segment imaging for widespread, multifocal, or unpredictable-distribution disease (extensive vasculitis, multifocal sarcoidosis, diffuse or recurrent rhabdomyolysis); MR spectroscopy or dedicated quantitative protocols for suspected mitochondrial myopathy in a research or specialist metabolic-medicine context, since this is not part of the routine generic protocol; and the dedicated tumor/infection pathway if a focal lesion identified during this work-up (e.g., an atypical diabetic myonecrosis or sarcoid nodule) cannot be confidently distinguished from a soft-tissue neoplasm or an infective collection.
2.2 Urgent Red Flags Requiring Expedited or Emergency Imaging
Unlike the companion neuromuscular master page, this indication group genuinely includes a systemic medical emergency — rhabdomyolysis with significant renal or metabolic risk — and this section should not be minimised.
| Red flag scenario | Recommended action |
|---|---|
| Rhabdomyolysis with markedly elevated creatine kinase and risk of acute kidney injury, hyperkalaemia, or disseminated intravascular coagulation | This is a medical emergency; prioritise clinical/nephrological management (aggressive fluid resuscitation, electrolyte and renal monitoring) — MRI, if performed at all, should support rather than delay this management |
| Suspected acute compartment syndrome complicating rhabdomyolysis or diabetic myonecrosis | Clinical–pressure emergency; refer immediately for surgical assessment and compartment pressure measurement rather than awaiting MRI |
| Rapidly progressive, systemically unwell presentation with muscle swelling and fever, raising concern for a superimposed infective process (pyomyositis, necrotising infection) rather than, or in addition to, a metabolic/systemic cause | Expedite assessment and imaging following the dedicated tumor/infection pathway red-flag guidance, since this changes management urgency and antibiotic/surgical decision-making |
| New systemic vasculitic presentation with multi-organ involvement (renal, cutaneous, neurological) alongside muscle symptoms | Not an MRI emergency per se, but warrants urgent rheumatological/internal medicine referral in parallel with imaging, given the risk of rapid multi-organ deterioration in some vasculitides |
| Suspected diabetic myonecrosis with diagnostic uncertainty in a systemically unwell patient in whom infection cannot be excluded clinically | Expedite imaging and correlate closely with inflammatory markers and, where needed, joint clinical-radiological decision-making, since the two conditions can closely mimic one another (Section 5.5) |
3. Preparation Reference
Universal MRI safety screening (implants, devices, claustrophobia) belongs to the general MRI preparation page and is not repeated here.
3.1 Anatomy-Specific Preparation Items
- Recent laboratory data should be available before the study is planned, specifically creatine kinase, renal function, and inflammatory markers where relevant — these materially inform both the urgency of the study and, in rhabdomyolysis specifically, whether contrast administration is appropriate given renal function.
- Diabetes history and control: relevant duration of diabetes, HbA1c, and known microvascular complications (retinopathy, nephropathy, neuropathy) should be documented when diabetic myonecrosis is suspected, since this context materially raises or lowers pre-test probability and should be explicitly available to the interpreting radiologist.
- Medication history: current or recent statin, corticosteroid, or other myotoxic drug exposure should be documented, since this directly informs the differential diagnosis and interpretation of any oedema or atrophy identified.
- Known systemic disease status: known sarcoidosis or vasculitis diagnosis, disease activity, and current immunosuppressive/corticosteroid treatment should be documented, since active treatment can significantly alter the expected imaging appearance (e.g., resolution of sarcoid nodules with steroid therapy).
- Symptom onset and evolution: acute, subacute, or chronic symptom timeline is particularly important in this indication group, since it directly affects interpretation (acute rhabdomyolysis versus chronic steroid-induced atrophy have essentially opposite expected signal patterns).
- Renal function and contrast eligibility: as elsewhere on this platform the general preparation page covers universal screening, but given the specific relevance of renal impairment risk in rhabdomyolysis and in some vasculitides with renal involvement, contrast eligibility should be actively re-checked rather than assumed at the point of this specific study.
- Skin marker at the site of palpable abnormality, exactly as in the companion pages, is valuable whenever a focal palpable lesion (diabetic myonecrosis, sarcoid nodule, vasculitic mass-like area) is the reason for referral.
3.2 Patient Positioning on the MRI System
- Position: supine for the great majority of limb studies; positioning otherwise follows the region of clinical concern rather than a fixed protocol default.
- Coil selection and centring: as with the companion pages, flexible surface coils sized to the region of interest are preferred; for suspected bilateral or multifocal disease (bilateral diabetic myonecrosis, multifocal vasculitis or sarcoidosis), bilateral or wider-FOV coverage should be planned from the outset rather than added reactively.
- Comfort and tolerance: patients with acute rhabdomyolysis or diabetic myonecrosis are frequently in significant pain, and adequate analgesia before scanning, along with sequence prioritisation (Section 8), is more consequential in this indication group than in many others on this platform.
- Immobilisation: standard limb support and padding; no disease-specific positioning manoeuvre is required for the entities in this group (unlike, for example, the provocative positioning required in the popliteal artery entrapment child page).
- Common positioning errors: an unnecessarily restricted FOV centred only on the palpable abnormality, missing a second, non-contiguous site in a multifocal process; failure to plan bilateral coverage when the clinical picture (known bilateral diabetic microvascular disease, systemic vasculitis) makes bilateral involvement plausible.
- Practical technologist checks before starting: confirm recent laboratory data (CK, renal function) are available; confirm whether bilateral or wider coverage is clinically indicated before finalising FOV; confirm contrast eligibility has been actively re-checked given the renal-risk context relevant to several entities in this group.
4. Standard Protocol Design
4.1 Mandatory Core Sequences
| # | Sequence | Plane | Status |
|---|---|---|---|
| 1 | Fluid-sensitive fat-suppressed T2 or STIR | Axial | Mandatory |
| 2 | T1-weighted, non-fat-suppressed | Axial | Mandatory |
| 3 | Fluid-sensitive fat-suppressed T2 or STIR | Coronal (long-axis overview) | Mandatory in modern protocol |
| 4 | T1-weighted fat-suppressed, pre-contrast | Axial | Conditional / mandatory in modern protocol when contrast is planned (Section 6) |
| 5 | T1-weighted fat-suppressed, post-contrast, matched to sequence 4 | Axial | Conditional — mandatory whenever contrast is administered |
4.2 Conditional Sequences
| Sequence | Indication | Plane |
|---|---|---|
| Bilateral/wider-FOV survey | Suspected multifocal or bilateral disease (diabetic myonecrosis, sarcoidosis, vasculitis) | Axial/coronal, wide FOV |
| Post-contrast fat-suppressed T1 with attention to enhancement pattern (rim, stippled, perivascular) | Diagnostic uncertainty between necrosis, infection, and inflammatory/vasculitic process | Axial, matched to pre-contrast |
| Diffusion-weighted imaging / ADC | Adjunct characterisation of necrotic versus viable/inflamed tissue, particularly in rhabdomyolysis and diabetic myonecrosis | Axial |
| Whole-body or extended multi-segment MRI | Widespread or unpredictable-distribution disease (extensive vasculitis, multifocal sarcoidosis, diffuse rhabdomyolysis) | Coronal/axial, whole-body protocol |
| MR spectroscopy (research/specialist context) | Suspected mitochondrial myopathy in a specialist metabolic-medicine work-up | As per specialist protocol; not part of the routine generic sequence set |
4.3 Rationale Summary Per Sequence
Fluid-sensitive fat-suppressed sequences are the primary detection tool across this entire indication group, depicting oedema-like signal in acute rhabdomyolysis, diabetic myonecrosis, sarcoid myopathy, and vasculitic myopathy alike. As throughout the companion muscle pages, this signal is non-specific in isolation; here the interpretive burden is particularly heavy because the differential (metabolic, vascular, granulomatous, inflammatory, and infective processes) is unusually broad, and distribution pattern, associated findings (haemorrhage, focal mass-like lesion, perivascular pattern), and clinical/laboratory context together carry most of the diagnostic weight.
T1-weighted non-fat-suppressed sequences provide anatomical baseline and are particularly important in this indication group for detecting intramuscular haemorrhage (a recognised, fairly common feature of rhabdomyolysis) and for characterising chronic fatty change, which is the expected appearance of longstanding corticosteroid myopathy and of some chronic denervation-overlap presentations, distinct from the acute oedema-predominant picture of rhabdomyolysis or vasculitic myopathy.
Post-contrast fat-suppressed T1-weighted imaging plays a genuinely diagnostic, pattern-defining role for several entities in this group, unlike the largely non-contrast neuromuscular master page. In rhabdomyolysis, a well-described “stippled” or dot-like enhancement pattern within a region of rim enhancement has been specifically described and correlates with underlying myonecrosis. In diabetic myonecrosis, small, focal, rim-enhancing fluid collections within an enlarged, oedematous muscle are a recognised and clinically useful pattern. In nodular sarcoid myopathy, homogeneous nodular enhancement, or the specific “three-stripe”/“dark star” pattern described below (Section 5), is a near-specific finding. In vasculitic myopathy, a perivascular, “fluffy” or patchy enhancement pattern centred on affected vessels has been described. Contrast is therefore genuinely diagnostically informative in this indication group, but its use must be weighed against renal function, particularly in the rhabdomyolysis and vasculitis sub-populations where renal impairment is a recognised risk (Section 6).
4.4 Sequence Matching and Cross-Sequence Consistency
Matched geometry between pre- and post-contrast fat-suppressed T1 sequences is important whenever contrast is used, for the same reasons described in the companion tumor/infection master page: reliable distinction between intrinsic T1-hyperintense content (subacute haemorrhage, common in rhabdomyolysis) and true enhancement depends on this matching. For serial follow-up — relevant in evolving rhabdomyolysis, in monitoring sarcoid myopathy response to steroid therapy, and in monitoring vasculitis under treatment — reproducing coil, FOV, and slice geometry at follow-up materially improves the reliability of interval comparison, exactly as emphasised throughout the companion pages.
4.5 Fat Suppression, Contrast-Specific or Region-Specific Technical Modifiers
Fat suppression requirements in this indication group broadly follow the principles established in the companion muscle master pages: spectral fat saturation is a reasonable default for a well-centred, moderate FOV; STIR is preferred whenever homogeneous suppression cannot be guaranteed, including for a wider bilateral FOV in suspected multifocal disease; and Dixon-based fat/water separation is a reasonable modern alternative, with the added advantage in this indication group of providing both an oedema-sensitive water channel and a fat-only channel that can help characterise chronic fatty change in, for example, longstanding corticosteroid myopathy, from a single acquisition. As throughout this platform, STIR must not be used on any post-contrast sequence; spectral or Dixon-based fat suppression should be used instead whenever post-contrast fat-suppressed imaging is required.
5. MRI Semiotics — Disease-Specific Imaging Findings (Generic-Level Overview)
This section provides the generic-level pattern-recognition framework for this indication group; each entity will have a dedicated, deeper child page covering its full semiotic detail, grading, and reporting specifics.
5.1 Rhabdomyolysis
The affected muscle is typically enlarged, with diffuse or patchy T2/STIR hyperintensity and oedema extending into the adjacent fascia and subcutaneous tissue in a substantial proportion of cases. Intramuscular haemorrhage, seen as areas of T1 hyperintensity, is a recognised and fairly common feature. On post-contrast imaging, a “stippled” enhancement pattern — dot-like or linear streaky foci of enhancement within an area of rim enhancement — has been specifically described and reported as the most common enhancement pattern in a detailed retrospective analysis, alongside a well-defined rectangular shape with a ragged margin on longitudinal imaging as a common morphological feature. Multiplicity of lesions within a single muscle compartment has been associated with a higher likelihood of subsequent peripheral neuropathy in the same series, an association worth flagging in the report though not yet an established, independently validated predictive tool.
5.2 Diabetic Myonecrosis
Typically affects the thigh (most often the quadriceps group) or, less commonly, the hip adductors, hamstrings, or calf, presenting as diffuse enlargement of the involved muscle group(s) with T2 hyperintensity and, characteristically, partial loss of the normal fatty intermuscular septa. Small, focal, rim-enhancing fluid collections within the affected muscle on post-contrast imaging are a recognised and clinically useful supportive feature. The T2-weighted sequence has been reported to have high sensitivity but comparatively limited specificity for muscle infarction specifically (as opposed to detecting active muscle disease more broadly), underscoring that the diagnosis rests on the combination of imaging pattern and the strong clinical context (long-standing, poorly controlled diabetes with microvascular complications) rather than on MRI signal alone.
5.3 Sarcoid Myopathy
Two principal, imaging-relevant patterns are recognised: a nodular type, in which MRI shows a highly characteristic appearance — an oval or elongated intramuscular nodule with a central, star-shaped area of low signal intensity (the “dark star” sign on axial images) surrounded by a rim of high T2/STIR signal, and, on coronal or sagittal imaging, an “three stripes” appearance with an inner low-signal stripe flanked by two outer high-signal stripes; nodules typically show homogeneous or peripheral enhancement on post-contrast imaging, and — usefully for follow-up — the central low-signal component has been observed to persist even after clinical and partial imaging response to steroid therapy, while the peripheral high-signal/enhancing component resolves; and a diffuse/myopathic type, in which MRI findings are frequently non-specific or, in some reported series, entirely normal despite histologically proven muscle involvement, reflecting the sparse distribution of granulomas in this form.
5.4 Vasculitic Myopathy
Muscle involvement in medium-vessel vasculitis (classically polyarteritis nodosa) and in some small-vessel/ANCA-associated vasculitides presents as focal or patchy areas of muscle T2/STIR hyperintensity, often centred on visibly abnormal, tortuous, or dilated intramuscular vessels, with a described “fluffy,” patchy, perivascular enhancement pattern on post-contrast imaging, sometimes with associated fascial or periosteal enhancement. Involvement is frequently asymmetric and multifocal, most often affecting the lower-limb muscles (quadriceps, hamstrings, gastrocnemius). This perivascular pattern, when identified, is a genuinely useful pointer toward a vasculitic aetiology and can meaningfully support the decision to proceed to (or defer) muscle biopsy.
5.6 Differential Diagnosis on MRI
| Differential | Key MRI features that argue for it | Key MRI features that argue against a metabolic/systemic-disease process | Decisive sequence or sign |
|---|---|---|---|
| Pyomyositis / infective myositis (see tumor/infection master page) | Systemic sepsis, discrete rim-enhancing abscess with a non-enhancing centre, clinical fever/raised inflammatory markers out of proportion to a metabolic cause | Absence of systemic infective picture; a pattern (stippled enhancement, dark star sign, perivascular pattern) specifically described for one of the entities in this group | Clinical/laboratory correlation is often decisive; imaging pattern alone can be genuinely ambiguous, particularly between diabetic myonecrosis and pyomyositis |
| Idiopathic inflammatory myopathy (see neuromuscular master page) | Symmetric, proximal, diffuse oedema without a focal mass-like or perivascular pattern; associated myositis-specific autoantibody profile | Focal, mass-like, or perivascular pattern more typical of a specific entity in this group | Distribution pattern and serological/clinical context |
| Soft-tissue tumour (see tumor/infection master page) | Solid, progressively enlarging, non-resolving mass without a clear metabolic/vascular trigger | A recognised entity-specific pattern (dark star/three-stripe sign for sarcoid, stippled enhancement for rhabdomyolysis) and a compatible systemic clinical context | Follow-up resolution or response to treatment (steroids, glycaemic control) strongly favours a metabolic/systemic-disease process over a neoplasm |
| Deep venous thrombosis | Compressible or non-compressible venous structure on duplex; a linear rather than muscular pattern of abnormality | Muscle-belly-centred oedema/necrosis rather than an isolated venous finding | Duplex ultrasound remains the first-line test; MRI muscle findings and venous thrombosis are not mutually exclusive and both should be considered |
6. Contrast Use Principles Specific to Muscle Metabolic and Systemic Disorders
Universal GBCA safety screening belongs to the general MRI preparation page; the project standard of macrocyclic agents applies. This indication group has a genuinely mixed relationship with contrast, more heterogeneous than either the largely non-contrast trauma/neuromuscular pages or the largely contrast-central tumor/infection page, and the decision should be made entity-by-entity rather than by a single blanket rule.
6.1 Non-Contrast Standard Protocol — Sufficient For
A substantial proportion of referrals — routine assessment of the extent of rhabdomyolysis in a patient with clear biochemical diagnosis and no focal complication suspected, follow-up of known, previously characterised diabetic myonecrosis or sarcoid myopathy where the non-contrast oedema/atrophy pattern already answers the clinical question, and most endocrine/drug-induced/toxic myopathy work-ups — can be adequately assessed without contrast, particularly given the genuine renal-risk considerations relevant to this population (rhabdomyolysis-associated acute kidney injury risk, vasculitis-associated renal involvement).
6.2 Gadolinium Indicated — Region-Specific Contexts
Contrast is genuinely diagnostically valuable, and should be actively considered where renal function allows, for: initial characterisation of suspected diabetic myonecrosis, where rim-enhancing fluid collections support the diagnosis and help exclude an abscess; initial characterisation of a suspected nodular sarcoid lesion, where the enhancement pattern contributes to the near-specific imaging appearance and to monitoring treatment response; suspected vasculitic myopathy, where the perivascular enhancement pattern adds diagnostic value beyond fluid-sensitive imaging alone; and any scenario in this indication group where distinguishing necrosis/infarction from a solid, potentially infective or neoplastic process is clinically important and cannot be confidently resolved on non-contrast sequences alone.
6.3 Post-Contrast Acquisition Timing
Standard early post-contrast imaging is sufficient for the entity-specific patterns described in Section 5 (stippled enhancement in rhabdomyolysis, rim enhancement in diabetic myonecrosis, nodular/peripheral enhancement in sarcoid myopathy, perivascular enhancement in vasculitis); dedicated dynamic or delayed-phase protocols are not part of the routine generic approach for this indication group. Injection time should be documented, and, given the renal-risk context specific to this population, the rationale for proceeding with or withholding contrast should be explicitly documented in the technique section of the report.
7. Reporting Essentials
7.1 Interpretation Framework
Given the breadth of this indication group, the report should explicitly reason through: acute versus chronic (oedema/haemorrhage-predominant versus atrophy/fatty-change-predominant, which broadly separates active metabolic/inflammatory processes from chronic drug- or disuse-related change); focal/mass-like versus diffuse (relevant to distinguishing diabetic myonecrosis or a sarcoid nodule from diffuse rhabdomyolysis or diffuse steroid atrophy); a specific entity-level pattern where present (stippled enhancement, dark star/three-stripe sign, perivascular pattern) versus a genuinely non-specific oedema pattern requiring clinical/laboratory correlation; and, where contrast was used, enhancing versus non-enhancing components, since this distinction is central to several of the entity-specific patterns described above.
7.2 Mandatory Reporting Checklist
The report should not omit: the muscle group(s) and compartment(s) involved and whether the distribution is focal, multifocal, or diffuse; presence and pattern of any enhancement, described using the entity-specific vocabulary above where a recognisable pattern is present; presence of intramuscular haemorrhage or necrosis; comparison with prior imaging where available, with explicit comment on interval change, particularly relevant for monitoring treated sarcoid myopathy or evolving rhabdomyolysis; technical limitations, including whether contrast was given or withheld and why; and an explicit statement correlating the imaging pattern with the clinical/laboratory context provided, rather than offering an imaging diagnosis in isolation.
7.3 Structured Reporting
Reports should follow the standard structure of indication, technique, comparison, findings, impression, and limitations, with the impression explicitly stating which entity or entities in this differential the pattern most supports, and explicitly flagging when the pattern is genuinely non-specific and requires clinical/laboratory correlation rather than allowing the report to imply false diagnostic certainty.
7.4 Incidental Findings — Clinical Decision Framework
- Usually benign: minor, age-appropriate degrees of fatty muscle change; small, stable, previously characterised sarcoid nodules in a patient under active surveillance with no new symptoms.
- Follow-up may be needed: a new, indeterminate focal muscle lesion in a patient with known sarcoidosis or vasculitis that does not clearly fit the expected pattern for their known disease.
- Urgent or clinically important: any finding raising concern for a superimposed infective process (abscess, gas) in a patient being worked up for a metabolic/systemic cause, since this changes management urgency substantially and should be communicated directly rather than folded into a routine report; and any unexpectedly extensive or bilateral finding suggesting more widespread disease than clinically appreciated, which may prompt escalation to a whole-body protocol.
8. MRI Technologist Pearls
8.1 Sequence Order Logic
Acquire the fluid-sensitive fat-suppressed sequence first, since it is the most broadly informative single acquisition across this entire indication group and provides a usable answer if the patient — frequently in significant pain, particularly in acute rhabdomyolysis or diabetic myonecrosis — cannot tolerate the full protocol; place contrast-enhanced sequences, when indicated, after the non-contrast anatomical sequences so that FOV and geometry are correctly established before contrast is administered.
8.2 Positioning Tricks
Confirm whether bilateral or wider coverage is genuinely required based on the clinical picture (known bilateral diabetic microvascular disease, systemic vasculitis, multifocal sarcoidosis) before finalising FOV, since these patients disproportionately have multifocal disease compared with the more focal presentations typical of the trauma protocol; use a skin marker at any palpable abnormality exactly as in the companion pages.
8.3 Fast Salvage Protocol
| Priority | Sequence | Approximate time | What it covers |
|---|---|---|---|
| 1 | Axial fluid-sensitive fat-suppressed (FS T2/STIR) | 3–4 min | Detects and localises oedema, necrosis, and the overall pattern of involvement |
| 2 | Axial T1-weighted | 2–3 min | Haemorrhage detection, anatomical correlation, chronic fatty change if present |
| 3 | Axial T1-weighted fat-suppressed, pre- and post-contrast (if contrast eligible and indicated) | 4–6 min | Entity-specific enhancement pattern (Section 5) supporting a specific diagnosis |
If the patient cannot tolerate further imaging, sequences 1 and 2 together represent a reasonable practical minimum for a clinically useful, if incomplete, answer across most of this indication group; omitting contrast (sequence 3) is a reasonable and sometimes necessary compromise given the renal-risk context specific to this population, and should be clearly documented as a limitation rather than silently absorbed into the report.
8.4 Common Avoidable Errors
| Error | Consequence | Prevention |
|---|---|---|
| Treating rhabdomyolysis MRI as the primary diagnostic/severity test | Delayed appropriate clinical/nephrological management | Ensure imaging supports, and does not substitute for or delay, clinical and laboratory management |
| FOV restricted to a single symptomatic region in a patient with plausible multifocal disease | Missed contralateral or additional-site involvement | Actively consider bilateral/wider coverage based on the systemic clinical context before finalising FOV |
| Contrast given without checking renal function in this specific population | Unnecessary renal risk in a group with genuinely elevated baseline risk | Actively re-confirm contrast eligibility rather than assuming it from a general screening form |
| Reporting non-specific oedema as if it were diagnostic of a specific entity | Inappropriate clinical action based on over-confident imaging language | Explicitly flag genuinely non-specific patterns as requiring clinical/laboratory correlation |
| Missing a superimposed infective process because attention is focused on the metabolic/systemic differential | Delayed antibiotic/surgical management of a coexisting infection | Actively consider and describe features (rim enhancement, gas, systemic sepsis) that would support a superimposed infective process |
9. Quality Control Checklist
- Coverage appropriate to the clinical picture, including bilateral/wider coverage where multifocal disease is plausible.
- Fluid-sensitive and T1-weighted sequences both of diagnostic quality across the region(s) of interest.
- Contrast eligibility actively confirmed (not merely assumed) given the renal-risk context relevant to this population; pre- and post-contrast sequences matched in geometry where contrast is used.
- No significant motion degradation, particularly relevant given the frequently significant pain in this patient population.
- Correct laterality and orientation labelling.
- Comparison with prior studies enabled where relevant to monitoring (treated sarcoid myopathy, evolving rhabdomyolysis).
- Report explicitly documents whether contrast was given or withheld, and why.
- Any pattern suggestive of a superimposed infective process actively considered and documented.
10. Advanced Technical Parameters
Open advanced technical reference
Fluid-sensitive fat-suppressed T2/STIR - Tissue contrast logic: as in the companion pages, maximises conspicuity of oedema, necrosis, and inflammatory change against a suppressed-fat background; the primary detection sequence across this entire indication group. - Acquisition design: representative parameters TR ≈ 3,500–6,000 ms, TE ≈ 40–80 ms, or STIR with field-strength-appropriate inversion timing, slice thickness ≈ 4–6 mm for a routine survey. - Diagnostic advantages: high sensitivity across essentially all entities in this group. - Limitations: fundamentally non-specific; distribution and associated findings, not signal characteristics alone, carry the diagnostic weight in this indication group more than in almost any other on this platform, given the breadth of the differential.
T1-weighted spin-echo - Tissue contrast logic: anatomical baseline, haemorrhage detection (particularly relevant in rhabdomyolysis), and chronic fatty-change characterisation (particularly relevant in corticosteroid myopathy). - Acquisition design: representative parameters TR ≈ 500–900 ms, TE ≈ 10–15 ms, slice thickness matched to the fluid-sensitive sequence. - Diagnostic advantages: haemorrhage dating; distinguishing acute oedema-predominant from chronic atrophy-predominant disease. - Limitations: low sensitivity to acute oedema in isolation; must be paired with the fluid-sensitive sequence.
Pre- and post-contrast fat-suppressed T1-weighted - Tissue contrast logic: as in the tumor/infection master page, solid/vascularised tissue enhances while necrotic or simple fluid components do not; the specific enhancement pattern (stippled, rim, nodular/three-stripe, perivascular) is what carries entity-specific diagnostic value in this indication group. - Acquisition design: representative parameters TR ≈ 500–900 ms, TE ≈ 10–15 ms, matched geometry to the pre-contrast sequence; subtraction is useful when intrinsic T1-hyperintense content (haemorrhage in rhabdomyolysis) could otherwise be mistaken for enhancement. - Diagnostic advantages: genuinely central to establishing several of the entity-specific diagnoses in this group, more so than in the largely non-contrast neuromuscular master page. - Limitations: renal-risk considerations specific to this population (Section 6) must be actively weighed before use; STIR must never be used post-contrast. - 2D vs 3D: 2D multiplanar remains the practical default for this indication group; 3D offers no specific, well-established advantage here beyond the general considerations already discussed in the companion master pages.
Bibliography for this section
11. Evidence Gaps & Ongoing Debate
- Prognostic/severity correlation of MRI findings with clinical outcome in rhabdomyolysis (e.g., whether the extent or multiplicity of lesions reliably predicts complications such as peripheral neuropathy or renal injury) is based on limited, mostly single-centre retrospective data, and should not be over-interpreted as an established predictive tool.
- Diagnostic accuracy of MRI for diabetic myonecrosis is described in mostly retrospective case series and pooled small-case reviews rather than large prospective diagnostic-accuracy studies; reported sensitivity of T2 hyperintensity for active muscle disease is high, but specificity for muscle infarction specifically is more limited, and this trade-off is not fully resolved by the current evidence base.
- Role of quantitative techniques (T2 mapping, diffusion, MR spectroscopy) across this indication group — for objective disease-activity assessment in vasculitic or sarcoid myopathy, or for mitochondrial myopathy characterisation — is an active but still largely research-level area rather than routine clinical practice.
- Optimal whole-body versus regional imaging threshold for suspected multifocal disease in this group (extensive vasculitis, multifocal sarcoidosis) is guided by expert practice rather than a specific validated threshold.
- Contrast necessity in borderline cases, particularly given the genuine renal-risk considerations specific to this population, remains a case-by-case clinical judgement rather than one settled by strong comparative evidence.
- AI-assisted pattern recognition for the entity-specific signs described in this page (dark star/three-stripe sign, stippled enhancement, perivascular pattern) is not yet a validated or standard clinical tool.
12. Evidence-Based References
A. Guidelines / Consensus / Society Recommendations
B. Systematic Reviews / Meta-analyses
C. Important Prospective / Original Studies
D. Technical MRI Papers
E. Landmark Historical References
End of document — MRI Muscle in Metabolic and Systemic Muscle Disorders — Generic Standard Protocol — MRIninja Master Page v1.0 — July 2026
Child Protocols
Clinical pages derived from this master protocol. These pages document what changes for specific indications.
No child protocols have been published yet.
Related Protocols
Recent PubMed search for this protocol